tbuckley/cabot-search huggingface dataset:
Phase I study of regorafenib in combination with vincristine and irinotecan in pediatric patients with recurrent or refractory solid tumors.
Authors: Michela Casanova, Francisco Bautista, Quentin Campbell Hewson, Guy Makin, Lynley V. Marshall, Arnauld Verschuur, Adela Canete, Nadège Corradini, Bart Ploeger, Udo Mueller, Hong Zebger-Gong, John Woojune Chung, Birgit Geoerger
Journal: Journal of Clinical Oncology (2020)

10507 Background: In pediatric patients with solid tumors, regorafenib demonstrated acceptable tolerability and preliminary anti-tumor activity. This phase 1 study evaluated regorafenib in combination with vincristine/irinotecan in pediatric patients with rhabdomyosarcoma (RMS) and other solid tumors. Methods: Patients with relapsed/refractory tumors received intravenous vincristine (1.5 mg/m 2 , Days 1 and 8) and irinotecan (50 mg/m 2 /day, Days 1–5) plus once-daily oral regorafenib (patients 6– &lt; 24 months: 60 mg/m 2 escalating to 65 mg/m 2 ; patients 2– &lt; 18 years: 72 mg/m 2 escalating to 82 mg/m 2 ) on either Days 1–14 (concomitant dosing) or Days 8–21 (sequential dosing) during each 21-day cycle. As per protocol, at least 50% of patients were required to have RMS. Results: At the time of the cut-off, of 21 treated patients (RMS, n = 12; Ewing sarcoma, n = 5; neuroblastoma, n = 3; Wilms tumor, n = 1), two had concomitant (72 mg/m 2 ) and 19 had sequential (72 mg/m 2 , n = 6; 82 mg/m 2 , n = 13) dosing. Median age was 10 years (1.5–17.0). Patients received a median of 3 cycles (1–17); dose reductions of irinotecan occurred in 62% of patients. Grade 3 dose-limiting toxicities were reported in both patients receiving concomitant dosing (peripheral neuropathy and liver injury; pain, vomiting, febrile aplasia) and one patient each in the sequential groups (rash and elevated AST; thrombocytopenia). Concomitant dosing was discontinued. The maximum tolerated dose and recommended phase 2 dose (RP2D) of regorafenib in the sequential combination was 82 mg/m 2 . The most common grade ≥3 treatment-emergent adverse events were neutropenia (71%), thrombocytopenia (33%), leukopenia (29%), anemia (24%), and ALT increased (24%). The response rate was 38%, including 1 complete (RMS) and 7 partial responders (5 RMS, 2 Ewing sarcoma); 3 of whom had prior irinotecan. Six (4 with alveolar subtype) of 12 patients with RMS had a response. Nine patients (43%) had stable disease (maximum duration 17 cycles). After the cut-off, partial response was reported for two additional patients (1 RMS, 1 Ewing sarcoma). Conclusions: Regorafenib can be combined at its single agent RP2D of 82 mg/m 2 with standard-dose vincristine/irinotecan (with appropriate dose modifications) in pediatric patients with refractory/relapsed solid tumors in a sequential dosing schedule. Clinical activity was observed in patients with sarcoma. Clinical trial information: NCT02085148.
CD49f Is a Novel Marker of Functional and Reactive Human iPSC-Derived Astrocytes
Authors: Lilianne Barbar, Tanya Jain, Matthew Zimmer, Ilya Kruglikov, Jessica S. Sadick, Minghui Wang, Kriti Kalpana, Indigo V.L. Rose, Suzanne R. Burstein, Tomasz Rusielewicz, Madhura Nijsure, Kevin A. Guttenplan, Angelique di Domenico, Gist Croft, Bin Zhang, Hiroko Nobuta, Jean M. Hébert, Shane A. Liddelow, Valentina Fossati
Journal: Neuron (2020)
螃蟹爪扎入咽部移动至颏下一例
Authors: 孙巧华, 董成功
Journal: BMJ (2008)

患者女,51岁,因咽部被螃蟹爪扎伤40 d,颏下肿物1周入院.患者40 d前吃螃蟹时不慎扎伤咽部左侧,当时疼痛较重,尤以吞咽时疼痛为甚.扎伤第2天左颌下区及颏下区出现肿胀伴轻度疼痛,在当地医院给予青霉素等药物静脉滴注1周后,咽部疼痛消失,颌下区及颏下区肿胀消退,但发现颏下区约1 cm ×1 cm×1 cm肿物,无明显疼痛,再次给予青霉素静脉滴注2周,无效,且肿物缓慢增大。
Baseline circulating tumor cell (CTC) count as a prognostic marker of PSA response and progression in metastatic castrate sensitive prostate cancer (mCSPC): Results from SWOG S1216, a phase III randomized trial of androgen deprivation plus orteronel (cyp17 inhibitor) or bicalutamide.
Authors: Amir Goldkorn, Catherine Tangen, Melissa Plets, Gareth Morrison, Alexander Cunha, Tong Xu, Jacek K. Pinski, Sue A. Ingles, Timothy Triche, Gary R. MacVicar, Daniel A. Vaena, Anthony W. Crispino, David James McConkey, Primo Lara, Maha H. A. Hussain, David I. Quinn, Nicholas J. Vogelzang, Ian Murchie Thompson, Neeraj Agarwal
Journal: Journal of Clinical Oncology (2020)

5506 Background: In mCSPC, androgen deprivation therapy (ADT) combined with chemotherapy or androgen receptor signaling inhibition (ARSI) is the new standard of care. Biomarkers that predict clinical outcomes with these therapies are needed. We hypothesized that CellSearch CTC count, an FDA-cleared biomarker in metastatic castrate resistant PC (mCRPC), may be a valuable biomarker in mCSPC. Methods: In S1216, peripheral blood was drawn with informed consent at registration (baseline), and CTCs were enumerated on the FDA-cleared CellSearch platform (Menarini) per standard manufacturer protocol. CTC counts were analyzed centrally for associations with 2 pre-specified trial intermediate endpoints: 7-month PSA (7mPSA) ≤ 0.2 ng/ml vs. 0.2–4.0 vs. &gt; 4.0, (intermediate endpoint for overall survival, OS); and progression-free survival (PFS) &lt; vs. &gt; 2 years. Because OS data have not matured, analysis was pooled and equal numbers of samples were analyzed from each treatment arm and outcome measure (7mPSA and PFS) as stipulated by the Data Safety Monitoring Committee. Results: From 2014 to 2017, 523 baseline samples were collected. In the 7mPSA analysis (n = 264), CTCs were detected in 38% of men, with a median of 4 CTCs in those with detectable CTCs. In the PFS analysis (n = 336), CTCs were detected in 37% of men, with a median of 3 CTCs in those with detectable CTCs. Adjusting for disease burden (minimal vs. extensive) and ADT status (already initiated or not) at the time of CTC measurement, men with undetectable CTCs were 6.1-fold more likely to attain 7mPSA ≤ 0.2 (OR 6.1, 95% CI 2.1-17.2, p &lt; 0.001) and 3.7-fold more likely to achieve &gt; 2 years PFS (OR 3.7, 95% CI 1.7-8.1, p &lt; 0.001) compared to men with baseline CTCs ≥ 5. Other cutpoints previously validated in mCRPC studies (CTC &lt; 5 vs. ≥5 and CTCs 0 vs. ≥1) also strongly discriminated 7mPSA and PFS with statistical significance in this mCSPC cohort. Conclusions: CTC count at the start of treatment for mCSPC was highly prognostic of 7-month PSA response (intermediate endpoint for OS) and of PFS at 2 years. To our knowledge, this is the first such strong evidence from a prospective phase 3 trial of this magnitude. Additional analyses are planned when the trial is fully reported. Baseline CTC count may serve as a valuable prognostic marker to discriminate men likely to respond favorably to hormonal therapies from those who may benefit from early alternate interventions.
Phase Ib clinical study of CBP501, cisplatin, and nivolumab administered every three weeks in patients with advanced refractory tumors: Efficacy in dose-escalation and expansion cohorts.
Authors: Marc Ryan Matrana, Frank Tsai, James M. Cleary, Suma Satti, Erkut Borazanci, Jacob Estes, Justin Moser, Khanh Tu Do, Lingling Du, Sunil Sharma, Vivek Khemka, Valentin Kolmakov, Takumi Kawabe, Geoffrey Shapiro
Journal: Journal of Clinical Oncology (2020)

3059 Background: CBP501 is a 12-amino acid G2 checkpoint abrogator and calmodulin-modulating peptide that increases platinum influx into tumor cells and induces tumor immunogenic cell death. CBP501 also suppresses platinum-induced release of cytokines by macrophages, lowers cancer stem cell populations, and reduces migration, invasion, and epithelial-mesenchymal transition of tumor cells. We report safety and efficacy outcomes from dose-escalation and expansion cohorts of a Phase Ib study of CBP501 combined with cisplatin and nivolumab (NCT03113188). Methods: An open-label Phase I trial was conducted using a 3+3 design: CBP501 and cisplatin were dosed simultaneously by 1h infusion Q3W at 4 different combined dose levels (CBP501: 16 or 25 mg/m 2 ; cisplatin: 60 or 75 mg/m 2 ) in the dose-escalation cohort. Nivolumab (240 mg) was dosed on the same day as a 1h infusion following CBP501/cisplatin. CBP501 and cisplatin were fixed at 25 and 60 mg/m 2 , respectively, in the expansion cohort. Eligible patients had pathologically confirmed, locally advanced or metastatic solid tumors, age ≥18 years, ECOG PS 0-1, life expectancy &gt; 3 months. The dose-expansion cohort had pretreated metastatic exocrine pancreatic cancer or microsatellite stable colorectal cancer (CRC). Scans were performed every 6 weeks while on study, then every 3 months. Results: The most common related adverse events (AEs) were infusion-related reaction (rash, itching, hives; n = 32/37 [Gr 1, n = 4; Gr 2, n = 28]; 86%) and anemia (n = 19/37 [Gr 1/2, n = 10; Gr 3, n = 9]; 51%). There were no additional safety signals other than those known for each agent. At January 9, 2020 (interim analysis), efficacy was evaluable in 17/19 patients in the dose-escalation cohort. Unconfirmed partial response was seen in 18% (3/17; 1 pancreatic, 1 colorectal, 1 cholangiocarcinoma), with &gt; 3 months stable disease (SD) in 41% (7/17), disease control in 41% (7/17), and &gt; 8 months overall survival (OS) in 53% (9/17). In the expansion cohort, efficacy was evaluable in 8/13 patients with pancreatic cancer: &gt; 4 months SD was 50% (4/8), median progression-free survival 4.2 months, and median OS 5.9 months (6/8 ≥3 rd line). The CRC cohort median OS for all CRC patients (n = 10) including the dose-escalation cohort (n = 5) was 17.5 months (10/10 ≥3 rd line). Conclusions: The triple-drug combination is reasonably tolerable with preliminary signs of efficacy in refractory solid tumors, including those in which cisplatin and nivolumab have limited single-agent activity. Clinical trial information: NCT03113188 .
Assessment forconsultation competence of resident general practitioners in Shanghai
Authors: Sun-fang Jiang, Juan Shou, Zhi-gang Pan, Xiang-jie Zhang, Ming-hui Peng, Shan-zhu Zhu
Journal: BMJ (2011)

：Objective To assessconsultation competence of resident general practitioners in Shanghai. MethodsStandardized patients (SPs) were employed as an assessment tool in exploring consultationcompetence of resident general practitioners ( GPs) , including clinical and communicationskills. Clinical skills included information collection, clinical thinking, healtheducation, out-patient history taking and recording and reception time management, andpatient-physician communication skills included building a good relationship, informationcollection and feedback, understanding issues from patient's perspective, sharinginformation and obtaining informed consent and close of consultation. Score rate definedas actual score of each item divided by total score of the domain was employed to assesscompetence of GPs in varied aspects. Results There were 157 resident GPs, 52 men and 105women, with an average age of (28 ±2) years. Overall score rate of clinical skillsaveraged (76 ±10) percent, and score rate of each item ranking from the highest to thelowest was reception time management (91 ±4) percent, out-patient history taking andrecording (80 ±14) percent, information collection (76 ±12) percent, clinical thinking(74 ±17) percent, health education (68 ±1) percent. Overall score rate of communicationskills averaged (74 ±12) percent, and score rate of each item ranking from the highest tothe lowest was building a good patient-physician relationship (86 ±3) percent,information collection and feedback (80 ±5) percent, sharing information and obtaininginformed consent (74 ±15 ) percent, close of consultation (62 ±27 ) percent andunderstanding issues from patient's perspective (43 ±0) percent. Conclusions Resident GPshave improved their consultation competence to certain extent after standardized training,but there still exist some weakness to be improved in them.
Correlation of serum visfatin and free fatty acid with insulin resistance in type 2 diabetes
Authors: Jing Wang, Yun Ruan, Qingying Tan, Yong Ruan, Xiujing Wang
Journal: BMJ (2014)

Objective
To investigate the association of serum visfatin and free fatty acid(FFA) with insulin resistance in type 2 diabetes mellitus (T2DM).


Methods
One hundred and nineteen patients with T2DM and 65 health subjects with normal glucose tolerance (NGT) were enrolled in the study.The T2DM patients were further classified as insulin resistant (HOMA-IR>2.8 mU/L, T2DM-IR group, n=61) and non-insulin resistant (HOMA-IR≤2.8 mU/L, T2DM-NIR group, n=58). Serum visfatin, free fatty acid and related clinical variables were measured, and HOMA-IR was calculated.


Results
The serum levels of visfatin and FFA in T2DM patients were significantly higher than those in healthy controls [(4.7±2.5) vs. (1.7±0.9) ng/L, t=-11.831, P<0.01; (1.65±0.69) vs. (0.61±0.21) mmol/L, t=-9.239, P<0.01]. The serum levels of visfatin and FFA in T2DM-IR group were significantly higher than those in T2DM-NIR group [(6.3±2.3) vs. (3.0±1.4) ng/L, P<0.01; (2.16±0.45) vs. (1.12±0.46) mmol/L, P<0.01]. Multiple regression analysis showed that FFA, fasting insulin level and waist/hip ratio (WHR) were independent risk factors of serum visfatin level(r=0.564, 0.267 and 0.188 respectively, all P<0.05).


Conclusion
Serum levels of visfatin and FFA are increased in T2DM, and they are closely associated with insulin resistance.


Key words: 
Diabetes mellitus, type 2; Visfatin; Free fatty acid; Insulin resistance
婴儿哭后屏气、抽搐发作
Authors: 吴明昌
Journal: BMJ (2009)

一个9个月的婴儿,脾气大,哭急了就憋气.近2周来更严重,哭后一口气上不来,脸色发青,两眼发直,四肢抽动,约1分钟停止,其后全身发软,歇5～6分钟才恢复正常,然后玩耍自如.反复发作3次.家长担心其是否患癫痫或颅脑有病。
Assessing social determinants of health in a safety-net oncology population: Use of an EHR-based screening and referral system.
Authors: Rebecca N. W. Tsai, Muhammad M. Qureshi, Stephanie Losi, Michael A. Dyer, Minh Tam Truong, Pablo Buitron de la Vega, Kimberley S. Mak
Journal: Journal of Clinical Oncology (2020)

e19072 Background: Routine electronic health record (EHR)-based screening and resource referral to address social determinants of health (SDOH) have been established in adult primary care clinics and the emergency department of New England’s largest safety-net hospital. The burden of SDOH in safety-net oncology patients is less well-studied. This study aimed to understand the social needs of this vulnerable patient population and evaluate the need for implementation of SDOH screening in the oncology clinic. Methods: Patients with lung or head and neck cancer seen in consultation in the Department of Radiation Oncology at Boston Medical Center between 3/2019-1/2020 were identified. EHRs were reviewed for receipt of THRIVE, an EHR-based screening and referral model addressing SDOH. Associations between patient demographics and SDOH screening were evaluated. Results: A total of 104 head and neck (n = 53; 51%) and lung (n = 51; 49%) patients were identified. Median age was 65 years (interquartile range 57.5-72). The majority of patients were male (71.2%), and English-speaking (82%). Whites, Blacks, and Asians comprised 43%, 38%, and 3% of patients, respectively. Fifteen patients were Hispanic (14%). Patients were most likely to have private health insurance (n = 41; 39%), followed by joint Medicare-Medicaid plans including senior and community health plans for elderly (n = 27; 26%), Medicaid (n = 17; 16%), and Medicare (n = 17; 16%). 83 of 104 patients (79.8%) were screened for at least one SDOH domain, with 55 patients (66%) screened before presentation in radiation oncology clinic. Transportation to medical appointments (16%), food insecurity (14%), and inability affording medications (10%) were the most prevalent concerns among these oncology patients. Housing insecurity, utilities, caregiving, unemployment, and education were identified social concerns for 4-5% of patients. The majority of patients who had at least one social need requested resources to assist them (71%). Age, gender, race, language, and insurance status were not associated with receipt of the SDOH screener (p≥0.1). Conclusions: Safety-net oncology patients report significant social needs. Routine SDOH screening and resource referral should be considered in these vulnerable patients.
Clinical analysis for 312 patients of acute carbon monoxide poisoning
Authors: 牛凤云, 郭艾萍, 郑小英, 高建华, 邢朝霞, 李茜
Journal: BMJ (2005)

目的 探讨急性一氧化碳中毒患者的发病特点、临床表现及不同治疗方法的疗效.方法回顾性分析1998年1月至2005年4月我院收治的312例急性一氧化碳中毒患者的中毒原因、发病年龄、性别、职业特点及临床表现、不同治疗方法的疗效. 结果急性一氧化碳中毒居室煤烟吸入占中毒原因的首位为84.6%(264/312),职业性中毒占2.9%(9/312);职业分布农民工占76.6%(239/312);87.1%(272/312)的中毒事件发生在冬春季节.头痛、头晕、恶心、乏力、意识障碍为主要症状;碳氧血红蛋白检测阳性率为52.9%;心肌酶谱和心电图异常率分别为52.2%和20.5%.昏迷≥4 h组脑水肿、肺水肿发生率分别为51.3%和15.8%,显著高于＜4 h组(20.9%,P<0.01;4.84%,P<0.05).血磁联合治疗组治愈率为91.7%,显著高于常规治疗组(40%,P<0.01)和高压氧治疗组(66.7%,P<0.05).结论一氧化碳接触史对急性一氧化碳中毒诊断具重要提示价值;意识障碍则是分级的主要依据;其严重并发症与昏迷时间密切相关;血磁联合治疗可提高其治愈率,并降低迟发脑病的发生率。
Research advances on long-term outcomes of endoscopic submucosal dissection for early esophageal cancer
Authors: Shi Wang
Journal: BMJ (2016)

With the improvement of endoscopic technology, an increasing number of early esophageal cancer is diagnosed by gastroscopy. Regardless of the size or submucous fibrosis of esophageal cancer, endoscopic submucosal dissection (ESD) allows en bloc resection and histologically complete resection of the tumor. ESD has been recognized as an optimal treatment modality for early esophageal carcinoma. Currently, short-term curative effects of early esophageal cancer after ESD have been proved satisfactory, but the long-term outcomes remain unclear. This paper reviews the research advances about the long-term outcomes of ESD, and focuses on the postoperative stenosis, the recurrence, metastasis and survival rates of patients, to provide treatment reference for clinicians.


Key words: 
Esophageal neoplasms; Gstroscopy; Follow-up studies
ARISTOTLE: A phase III trial comparing concurrent capecitabine with capecitabine and irinotecan (Ir) chemoradiation as preoperative treatment for MRI-defined locally advanced rectal cancer (LARC).
Authors: David Sebag-Montefiore, Richard Adams, Simon Gollins, Leslie M. Samuel, Robert Glynne-Jones, Robert Harte, Nicholas West, Philip Quirke, Arthur Sun Myint, Simon P Bach, Philip Parsons, Stephen Falk, Amandeep Singh Dhadda, Vivek Misra, Nick Brown, Gina Brown, Mark Harrison, Laura White, Marian Duggan, Andre Lopes
Journal: Journal of Clinical Oncology (2020)

4101 Background: Phase II studies reported high pathological complete response (pCR) rates and acceptable toxicity using irinotecan and fluoropyrimidine chemoradiation in LARC (ISRCTN:09351447). Methods: This phase III, multicentre, open-label trial funded by Cancer Research UK, randomly assigned (1:1) patients with MRI defined LARC threatening or involving resection margins without metastases, to pre-operative radiotherapy (RT) 45Gy/25 fractions combined with either capecitabine 900mg/m 2 (CRT) or 650 mg/m2 bd weekdays with Irinotecan iv once-weekly 60mg/m2 weeks 1-4 (IrCRT). The primary endpoint is disease-free survival (DFS). Secondary endpoints include treatment compliance, safety and pCR. Results: 75 UK sites randomised 564 eligible patients from Oct/11 to July/18; 284 to CRT and 280 to IrCRT. 370 (66%) male; median age 61 years (range:29-83). Staging in both arms was similar: mrT3 (432/564(77%), mrT4 (89/564(16%); mrCRM involved (275/564(49%); threatened ≤1mm (215/564(38%). Compared with CRT, IrCRT patients were less likely to receive 45Gy RT (207/276(75%) vs 251/283(89%), p &lt; 0.001) or receive ≥90% capecitabine dose in 188/276(68%) vs 253/283(89.4%)p &lt; 0.001). A total of 204/276(74%) received ≥90% irinotecan dose. The grade 3-4 gastrointestinal adverse event rate was 21%(58/276) with IrCRT and 12%(34/283) with CRT (p = 0.004). Patients receiving IrCRT had significantly more diarrhoea 38/276(13.8%) vs 10/283(3.5%)p &lt; 0.001) and neutropenia 27/276(9.8%) vs 3/283 (1.1%) p &lt; 0.001). Two CRT and three IrCRT patients experienced a treatment related death. 237/276(86%) IrCRT and 241/283(85%) CRT patients had surgery. The median time from end of RT to surgery(10.6 weeks), the surgical procedure APE 262/478(55%), AR 189/478(40%), Hartmann’s 10/478(2%); and the surgical complications(any event) 38%(181/478) were similar in both arms. The pCR rate is available in &gt; 95% patients and is 20.2%(46/228) for IrCRTvs.17.4%(40/230) for CRT (p = 0.45), A &gt; 84% CRM-ve resection rate is similar in both arms. Conclusions: For patients with MRI defined high risk LARC low rates of CRM involvement were observed in both arms reflecting high quality multidisciplinary care. The addition of irinotecan did not significantly improve the pCR rate, was associated with a decrease in the RT and capecitabine compliance and a higher rate of adverse events. Surgical procedure or complications were unaffected. Longer follow-up is required to assess DFS and translational data. Clinical trial information: 09351447 .
Retrospective analysis of intraoperative radiation therapy with low-kilovoltage x-rays (IORT-LK) in soft tissue sarcomas (STS).
Authors: Waldec Jorge David, Rodrigo De Morais Hanriot, Raphael Paulo Di Paula Filho, Pedro Alexandre Ismael Amaral Silva, Marcos Andre De Sa Barreto Costa, Cheng Tzu Yen, Evandro Sobroza de Mello
Journal: Journal of Clinical Oncology (2020)

e23575 Background: STS include a heterogeneous group of malignancies that arises from or into connective tissues and limbs are the preferential primary sites. An adequate local control with multimodality therapy can be obtained in most cases. An additional approach, that is, the IORT-LK is able to deliver high dose to risky areas for recurrence, minimizing the toxicity to structures around the target. Such an importance is even greater in abdominal sarcomas, because there is some difficulty in removing the whole neoplasia with clear margins. IORT-LK has the advantage of higher Relative Biological Effectiveness (RBE), a mathematical model that measures the potential for tumour double-strand break (radiation effectiveness), that is close to Proton beam and higher than electron beam. Nevertheless, IORT-LK is not free of complications. It has been reported peripheral neuropathy and enteritis, in cases of limb and abdominal STS, respectively. Methods: In this retrospective study from a single Brazilian institution (Hospital Alemão Oswaldo Cruz), we reported 6 patients with histologically confirmed STS, that underwent IORT-LK (Intrabeam - Carl Zeiss). There are 3 male and 3 female patients, with a median age 48 years, and mean of 39 years. The histological subtypes are as follows: fibromyxoid sarcoma, high grade pleomorphic sarcoma, desmoid tumor, chondrosarcoma, dedifferentiated liposarcoma and malignant schwannoma - one subtype for each patient. The primary sites are: inferior limb (3), superior limb (1) and abdomen (2). Results: IORT-LK was administered in doses that ranged from 14 to 15 Gy to the involved area. Two patients, each one with a limb STS, received also neoadjuvant chemotherapy. With a mean follow-up of 30 months, there is no local recurrence among the 6 patients reported. The first patient received the IORT-LK in April, 2017 and the last one in July, 2019. All of them had clinical observation up-to-dated on January, 2020. No serious complications were observed, but one patient had a moderate local infection. Conclusions: The therapy was well tolerated. We must emphasize that dose previously used by Brussiers was slightly superior than ours but with electrons and not Low-Kylovoltage. In his pilot study it was used 17 Gy for treatment of abdominal sarcomas. In sum, we believe that IORT-LK has higher RBE than previous available equipment and can improve local control of STS, mainly those that arise on the extremities. Future studies must be carried out to confirm our initial impression.